News About: R&D


More international pressure to waive local clinical study for new drugs.

American pharmaceutical research based manufacturers association (PhRMA) requested USTR to designate Korea along with Argentina as the country of first convention (PFC) in connection with the exemption of loca...

R&D investment found 4% level of net sales.

Domestic drug makers revealed their hot enthusiasm in developing new drugs amid expectation of the first birth of domestic new drug this year. Despite a difficult management environment under the IMF economic crisis t...

Patent dispute on Interferon anticancer drug ended.

A 8 year patent dispute on Interferon between Cheil Jedang and Roche, a Swiss multinational pharmaceutical corporation, has been ended recently. The 2nd division of the Supreme Court (Chief Chancellor: Cho Moo-jae)...

New Drug R&D Union to build up technology mart.

So called Pharma-Tech Plaza, a technological cooperation market, seems to be established this year, where respective specialists in the new drug research and development and their projects would be gathered together f...

Hot competition in commercialization of the first new drug in Korea.

Since the second half of 1980s the research oriented pharmaceutical companies have made quite an investment for an R&D of new drug discovery, and now is the time for these companies to visualize their fruit for the fi...

1999 perspective in drug industry: R&D of new drugs

After the adoption of product patent system in 1987, the local drug industry has exerted its best efforts for developing new drugs. Now, after a long dark tunnel, a small spot light seems to shine. SKI2053R (Sunfla...

New drug R&D no hindered by IMF crisis report meeting

Korea Union of New Drug Research and Development (Chairman: Lim Sung-ki) (KUNRD) plans to held a report meeting of the G7 research project at the international conference hall of Korea Institute of Science and ...

Amicable M&A possibility exposed to multinational corporation

Korea government eliminated restrictive provisions in stock markets, allowing foreigners to purchase up to 55% shares of a domestic firm, which provides many ossibilities for domestic pharmaceutical companies ...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.